JP2022003042A5 - - Google Patents

Download PDF

Info

Publication number
JP2022003042A5
JP2022003042A5 JP2021147620A JP2021147620A JP2022003042A5 JP 2022003042 A5 JP2022003042 A5 JP 2022003042A5 JP 2021147620 A JP2021147620 A JP 2021147620A JP 2021147620 A JP2021147620 A JP 2021147620A JP 2022003042 A5 JP2022003042 A5 JP 2022003042A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
amd
prevention
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021147620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022003042A (ja
JP7754480B2 (ja
Filing date
Publication date
Priority claimed from JP2018519309A external-priority patent/JP7037186B2/ja
Application filed filed Critical
Publication of JP2022003042A publication Critical patent/JP2022003042A/ja
Publication of JP2022003042A5 publication Critical patent/JP2022003042A5/ja
Priority to JP2023177353A priority Critical patent/JP2024016045A/ja
Application granted granted Critical
Publication of JP7754480B2 publication Critical patent/JP7754480B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021147620A 2015-10-14 2021-09-10 加齢黄斑変性のための高用量スタチン Active JP7754480B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023177353A JP2024016045A (ja) 2015-10-14 2023-10-13 加齢黄斑変性のための高用量スタチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562241522P 2015-10-14 2015-10-14
US62/241,522 2015-10-14
JP2018519309A JP7037186B2 (ja) 2015-10-14 2016-10-14 加齢黄斑変性のための高用量スタチン

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018519309A Division JP7037186B2 (ja) 2015-10-14 2016-10-14 加齢黄斑変性のための高用量スタチン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023177353A Division JP2024016045A (ja) 2015-10-14 2023-10-13 加齢黄斑変性のための高用量スタチン

Publications (3)

Publication Number Publication Date
JP2022003042A JP2022003042A (ja) 2022-01-11
JP2022003042A5 true JP2022003042A5 (https=) 2022-06-14
JP7754480B2 JP7754480B2 (ja) 2025-10-15

Family

ID=58517927

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018519309A Active JP7037186B2 (ja) 2015-10-14 2016-10-14 加齢黄斑変性のための高用量スタチン
JP2021147620A Active JP7754480B2 (ja) 2015-10-14 2021-09-10 加齢黄斑変性のための高用量スタチン
JP2023177353A Withdrawn JP2024016045A (ja) 2015-10-14 2023-10-13 加齢黄斑変性のための高用量スタチン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018519309A Active JP7037186B2 (ja) 2015-10-14 2016-10-14 加齢黄斑変性のための高用量スタチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023177353A Withdrawn JP2024016045A (ja) 2015-10-14 2023-10-13 加齢黄斑変性のための高用量スタチン

Country Status (13)

Country Link
US (2) US11331295B2 (https=)
EP (1) EP3362063B1 (https=)
JP (3) JP7037186B2 (https=)
AU (1) AU2016338540B2 (https=)
CA (1) CA3001661C (https=)
DK (1) DK3362063T3 (https=)
ES (1) ES2941347T3 (https=)
FI (1) FI3362063T3 (https=)
IL (1) IL258604B2 (https=)
MX (1) MX391944B (https=)
PH (1) PH12018500745B1 (https=)
WO (1) WO2017066529A1 (https=)
ZA (1) ZA201803097B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11789024B2 (en) 2017-05-09 2023-10-17 Massachusetts Eye And Ear Infirmary Biomarkers for age-related macular degeneration
EP3654941A1 (en) * 2017-07-17 2020-05-27 Keith Roizman Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases
WO2019079515A1 (en) * 2017-10-17 2019-04-25 Apeliotus Technologies, Inc. FUNCTIONAL BIOMARKERS FOR STATIN-BASED TREATMENT IN AGE-RELATED MACULAR DEGENERATION (AMD)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030065020A1 (en) * 2001-07-13 2003-04-03 Catharine Gale Treatment of macular degeneration
CA2478317A1 (en) 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
WO2005083430A1 (en) 2004-02-25 2005-09-09 Massachusetts Eye & Ear Infirmary Biomarkers for age-related macular degeneration (amd)
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006083533A2 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
US20100034749A1 (en) 2006-07-10 2010-02-11 Medigene Ag Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases
JP2008268506A (ja) * 2007-04-19 2008-11-06 Fuji Xerox Co Ltd 現像装置、像保持体ユニットおよび画像形成装置
WO2009023411A1 (en) 2007-08-09 2009-02-19 Bausch & Lomb Incorporated Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases
US20120156202A1 (en) 2010-11-05 2012-06-21 Shantha Totada R Age related macular degeneration treatment
EP3041479B1 (en) 2013-09-06 2023-04-26 Vanda Pharmaceuticals Inc. Treatment of cyr61- and vegf-mediated conditions
WO2016009430A1 (en) 2014-07-14 2016-01-21 Yeda Research And Development Co. Ltd Reduction of aging-induced type i interferon signaling at the brain's choroid plexus or within the cns for treatment of disease or injury of the cns
MX383117B (es) 2014-07-31 2025-03-13 Anji Pharmaceuticals Inc Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.

Similar Documents

Publication Publication Date Title
JP2022003042A5 (https=)
JP2022177142A5 (https=)
JP6336914B2 (ja) 脳卒中の治療のためのホルボールエステルの組成物および使用方法
HRP20250797T1 (hr) Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom
KR19980701959A (ko) 신규 제약 조합물
EP2987491B1 (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
US20110098314A1 (en) Statins for the treatment of ocular hypertension and glaucoma
ES2383822T3 (es) Formulaciones para el tratamiento de anomalías de lipoproteínas que comprenden una estatina y un derivado de metilnicotinamida
CN101939001B (zh) 用于治疗卵巢癌的含有紫杉醇的组合
IL287536B1 (en) Compositions and methods for use of cannabinoids for neuroprotection
EA009668B1 (ru) Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
US20200188405A1 (en) Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
JP2010215667A (ja) 外網膜の疾患を処置する薬剤を製造するためのβ−アドレナリン作用受容体アンタゴニストの使用
JP2018530586A5 (https=)
US20120208883A1 (en) Treatment of oncological diseases
JP7754480B2 (ja) 加齢黄斑変性のための高用量スタチン
JP2019518736A (ja) 併存疾患としてアパシーを伴うアルツハイマー病の治療における使用のための5−ht6受容体アンタゴニスト
EP3193900B1 (en) Compositions based on saffron for the prevention and/or treatment of corneal dystrophies.
JP4824954B2 (ja) 口内炎治療のための口腔用組成物
KR20130137623A (ko) 림프 부종 예방 치료제
CN1455679A (zh) Melagatran用于制备治疗局部缺血症的药物的用途
RU2007112950A (ru) Новые производные 3,5-секо-4-норхолестана и их применение
EP3558378A1 (en) Low dose drug combinations for use in preventing and treating neuronal damage
NZ742203B2 (en) High-dose statins for age-related macular degeneration
Yarangümeli et al. Effects of betaxolol and flunarizine on visual fields and intraocular pressure in patients with migraine